Trial reportJCO oncology practice2026
Does Electronic Symptom Monitoring Improve Symptom Burden and Self-Efficacy Among Chemotherapy and Surgery Patients Across Six Cancer Centers?
Trial report in JCO oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThe multicenter Symptom Management Implementation of Patient Reported Outcomes in Oncology Consortium developed electronic Symptom Management (eSyM), an electronic health record-based symptom management program, to reduce acute care utilization. We hypothesized that implementing eSyM would also improve self-reported symptom burden and self-efficacy.
methodseSyM was deployed via a pragmatic stepped-wedge cluster randomized trial for adults who started chemotherapy or had surgery for confirmed or suspected GI, gynecologic, or thoracic malignancies across six cancer centers from 2019 to 2023. In parallel, we administered a survey to two distinct cohorts: patients treated before and after eSyM deployment (ie, pre-live and post-live). A REDCap-based survey collected demographic and clinical characteristics and assessed six Patient-Reported Outcomes Measurement Information System measures: self-efficacy for symptom management, pain interference, anxiety, fatigue, depression, and physical function. Differences in mean T-scores were derived for the post-live versus pre-live cohorts among chemotherapy and surgery recipients. Multivariable regression models controlled for relevant patient and clinical characteristics.
resultsThe pre-live cohort included 1,043 respondents (490 chemotherapy and 553 surgery); the post-live cohort included 1,046 respondents (535 chemotherapy and 511 surgery). After controlling for other clinical and demographic factors, the post-live chemotherapy cohort reported statistically significantly lower fatigue and anxiety, but the reductions did not meet the clinically meaningful threshold (adjusted mean T-score difference: -1.3 and -1.8, respectively;
conclusioneSyM deployment was associated with reduced symptom burden, but clinically meaningful differences were only observed in fatigue and anxiety scores among surgical patients. Future studies should investigate the mechanisms by which symptom reporting affects patient outcomes, such as improving patient-clinician communication, enhancing clinician attention to symptom management, or increasing patient self-efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.